S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Mirza Mansoor Raza, a director at Sera Prognostics , Inc. (NASDAQ:SERA), recently sold shares of the company’s Class A common stock, according to a filing with the Securities and Exchange Commission. The transaction, which took place on March 6, involved the sale of 99 shares at a weighted average price of $4.16 per share, resulting in a total transaction value of $411.
The sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). This transaction was part of a mandated "sell to cover" arrangement by Sera Prognostics and was not a discretionary action by Raza.
Following the transaction, Raza continues to hold 43,885 shares of Sera Prognostics. The shares were sold as part of a block trade at prices ranging from $4.07 to $4.24. The company maintains a FAIR financial health score according to InvestingPro metrics, which offers additional ProTips and detailed financial analysis for informed investment decisions.
In other recent news, Sera Prognostics has made several noteworthy announcements. The company terminated its "at-the-market" offering prospectus, initially intended to raise up to $50 million through the sale of Class A common stock, as per a recent SEC filing. Despite this halt, Sera Prognostics has launched a new public offering of Class A common stock and pre-funded warrants, with proceeds aimed at expanding U.S. operations, EU growth, and FDA approval efforts for its PreTRM test. This offering is managed by Jefferies, TD Cowen, William Blair, and RBC Capital Markets, and is contingent on market conditions.
Additionally, Sera Prognostics revealed topline results from its PRIME study, focusing on improving neonatal outcomes through prematurity risk assessment. These findings will be discussed in detail at the upcoming SMFM 2025 Pregnancy Meeting. Following this, the company plans a conference call and live audio webcast to delve deeper into the study’s outcomes. These developments indicate Sera Prognostics’ ongoing commitment to advancing its diagnostic tests and expanding its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.